UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): March 5, 2008
EMERGING VISION,
INC.
(Exact
name of Registrant as specified in its charter)
|
New York
|
|
|
|
001-14128
|
|
|
11-3096941
|
|
(State
or other jurisdiction of incorporation)
|
|
|
|
(Commission
File Number)
|
|
|
(IRS
Employer Identification No.)
|
100
Quentin Roosevelt Boulevard
Garden
City, New York 11530
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (516) 390-2100
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02
|
Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain
Officers.
|
On March
5, 2008, Dr. Robert Cohen resigned as a director on Emerging Vision, Inc.’s (the
“Company”) Board of Directors and its Executive Committee.
Earlier
this month, Cohen Fashion Optical, Inc., of which Dr. Cohen is a chief executive
and shareholder, sold its retail optical franchise division to an affiliate of
Houchens Industries, Inc. As a component of such sale, Dr. Cohen
executed an employment agreement and other agreements with such affiliate,
which, among other things, prohibit Dr. Cohen from serving as a director on the
Company’s Board.
The
Nominating Committee of the Board has received, and is evaluating, resumes of
candidates to fill the vacancy on the Board created by Dr. Cohen’s
resignation. Upon recommendation of the Nominating Committee, the
Board will consider and elect a new director to fill such vacancy.
[Signature
on following page]
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
EMERGING
VISION, INC.
By: /s/
Brian P.
Alessi
Name:
Brian P. Alessi
Title: Chief
Financial Officer
Date: March
7, 2008